CytoAgents is a biotechnology company focused on the the treatment of COVID-19, Influenza, and other viral infectious diseases.
CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation also known as cytokine storm.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 10, 2021 | Grant | $2M | 1 | National Institutes of Health | — | Detail |
May 13, 2020 | Grant | $1.60M | 1 | National Institutes of Health | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | Yes | Grant |